|
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 36346688 | Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group. | Clin Cancer Res | 2023 |
| 37956387 | Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. | JCO Clin Cancer Inform | 2023 |
| 37094596 | Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. | Lancet Haematol | 2023 |
| 36951526 | Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. | J Natl Cancer Inst | 2023 |
| 36566574 | Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. | Eur J Cancer | 2023 |
| 36534942 | Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. | J Clin Oncol | 2023 |
| 36724417 | Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 37956387 | Osteosarcoma Explorer: A Data Commons With Clinical, Genomic, Protein, and Tissue Imaging Data for Osteosarcoma Research. | JCO Clin Cancer Inform | 2023 |
| 36951526 | Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group. | J Natl Cancer Inst | 2023 |
| 37094596 | Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. | Lancet Haematol | 2023 |
| 36724417 | Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Clin Oncol | 2023 |
| 36534942 | Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. | J Clin Oncol | 2023 |
| 36566574 | Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. | Eur J Cancer | 2023 |
| 36221002 | Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. | Br J Cancer | 2022 |
| 35390316 | Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. | Am J Pathol | 2022 |
| 36221002 | Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children's Oncology Group. | Br J Cancer | 2022 |
| 35887382 | Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma. | Int J Mol Sci | 2022 |
| 35377710 | Reply to R. Lakhotia et al. | J Clin Oncol | 2022 |
| 35377710 | Reply to R. Lakhotia et al. | J Clin Oncol | 2022 |
| 35390316 | Deep Learning of Rhabdomyosarcoma Pathology Images for Classification and Survival Outcome Prediction. | Am J Pathol | 2022 |
| 35887382 | Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma. | Int J Mol Sci | 2022 |
| 33201239 | Deployment and Psychological Correlates of Suicide Ideation: A Prospective, Longitudinal Study of Risk and Resilience Among Combat Veterans. | Mil Med | 2021 |
| 33744718 | STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. | Eur J Cancer | 2021 |
| 34166060 | Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. | J Clin Oncol | 2021 |
| 33684925 | Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. | Blood | 2021 |
| 33722853 | <i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. | Mol Cancer Ther | 2021 |
| 33603563 | Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. | Sarcoma | 2021 |
| 34023919 | Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. | Cancer Chemother Pharmacol | 2021 |
| 33372952 | Germline Cancer Predisposition Variants inâ¿¿Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Natl Cancer Inst | 2021 |
| 33201239 | Deployment and Psychological Correlates of Suicide Ideation: A Prospective, Longitudinal Study of Risk and Resilience Among Combat Veterans. | Mil Med | 2021 |
| 34570655 | Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. | J Clin Oncol | 2021 |
| 33744718 | STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. | Eur J Cancer | 2021 |
| 33684925 | Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. | Blood | 2021 |
| 33722853 | <i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. | Mol Cancer Ther | 2021 |
| 33603563 | Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. | Sarcoma | 2021 |
| 34570655 | Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. | J Clin Oncol | 2021 |
| 34166060 | Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. | J Clin Oncol | 2021 |
| 34023919 | Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. | Cancer Chemother Pharmacol | 2021 |
| 33372952 | Germline Cancer Predisposition Variants inâ¿¿Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. | J Natl Cancer Inst | 2021 |
| 31479512 | Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. | Int J Cancer | 2020 |
| 32191290 | Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. | JAMA Oncol | 2020 |
| 31794076 | Targeting fusions for improved outcomes in oncology treatment. | Cancer | 2020 |
| 32002305 | Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. | Oncoimmunology | 2020 |
| 32492302 | Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. | N Engl J Med | 2020 |
| 32923144 | Tumor mutational burden is not predictive of cytotoxic chemotherapy response. | Oncoimmunology | 2020 |
| 32747422 | High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. | Mol Cancer Ther | 2020 |
| 32914879 | ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. | Cancer | 2020 |
| 33296034 | Relationship between tumor mutational burden and maximum standardized uptake value in 2-[<sup>18</sup>F]FDG PET (positron emission tomography) scan in cancer patients. | EJNMMI Res | 2020 |
| 31479512 | Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. | Int J Cancer | 2020 |